Shots:

• The P-III ADVANCE trial evaluates efficacy- safety & tolerability of atogepant (PO- 10/30/60 mg- qd) vs PBO in 910 patients with EM who experienced 4-14 migraine days/mos.
• Results: patients achieving a ≥50% reduction in monthly migraine days (55.6%/58.7%/60.8% vs 29.0%) @12wks. & all doses were well tolerated. Additionally- 30/60 mg doses showed improvements in all six 2EPs- including a reduction in acute medication use & function impairment measures in AIM-D & MSQ v2.1
• Atogepant is a CGRP receptor antagonist. If approved- it will be 1st oral gepant for EM & is currently under FDA’s review with an expected regulatory decision in late Q3’21

  | Ref: AbbVie | Image: abbvie